Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its lead candidate, Lucid-MS, toward a randomized, double-blind, placebo-controlled phase 2 trial in multiple sclerosis (MS) after the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application. The clearance marks a critical step for a therapy that takes a different approach to treating MS: rather than suppressing the immune system, Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (PAD2) designed to target demyelination directly.
This distinction matters because current MS therapies primarily focus on modulating or suppressing immune activity, which can reduce relapses but often does not address the underlying loss of myelin that drives disability progression. By aiming to prevent and reverse myelin degradation, Lucid-MS could potentially fill a significant gap in MS treatment. Preclinical models have shown the compound to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. If the phase 2 trial confirms these effects in humans, Lucid-MS could become a foundational therapy for patients who continue to experience disease progression despite existing treatments.
The FDA's acceptance of the IND application also underscores the credibility of Quantum's research. The company's collaboration with Massachusetts General Hospital and Harvard Medical School on the [¹⁸F]3F4AP PET imaging tracer further strengthens its position. This tracer is being evaluated as a method to visualize and measure demyelination, which could provide a powerful tool for monitoring treatment response and accelerating drug development.
Quantum BioPharma is not alone in advancing therapies for unmet medical needs. The broader biotech landscape includes companies such as Novartis AG (NYSE: NVS), which received FDA approval for Pluvicto(R) in combination with an androgen receptor pathway inhibitor for certain patients with metastatic hormone-sensitive prostate cancer; Merck & Co. Inc. (NYSE: MRK), whose supplemental Biologics License Application for ENFLONSIA(TM) was accepted by the FDA to expand its indication for certain children at increased risk for severe respiratory syncytial virus disease; TG Therapeutics Inc. (NASDAQ: TGTX), which initiated a phase 2 trial of BRIUMVI(R) in adults with treatment-resistant schizophrenia; and Bristol-Myers Squibb Company (NYSE: BMY), which reported positive phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in heavily pretreated relapsed and refractory multiple myeloma. These developments highlight a shared momentum across the industry, but Quantum's focus on remyelination sets it apart in the MS space.
For investors, the IND clearance reduces regulatory risk and brings Quantum closer to a major value inflection point. A successful phase 2 trial could position Lucid-MS as a novel therapy with blockbuster potential. The company also retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd Wellness Inc., which sells an OTC version of UNBUZZD(TM), and holds rights to royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
To view the full press release, visit https://ibn.fm/lCey9.
